Aura Biosciences, Inc.
NGM: AURALive Quote
About Aura Biosciences, Inc.
Healthcare
Biotechnology
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Aura Biosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -73.5%, which indicates that capital utilization is currently under pressure.
At a current price of $6.80, AURA currently sits at the 78th percentile of its 52-week range (Range: $4.34 - $7.48).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$656.50M
Trailing P/E
--
Forward P/E
-3.35
Beta (5Y)
0.35
52W High
$7.48
52W Low
$4.34
Avg Volume
248K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App